MVision AI’s guideline-based AI segmentation, GBAIS, will now be available in Canada after the company signed a new distribution partnership with Medron Medical Systems, subject to approval from Health Canada.
The collaboration authorizes Medron Medical Systems to distribute products and services of MVision AI throughout Canada. Medron Medical Systems and MVision AI are devoted to helping oncology departments receive exceptional and consistent radiotherapy machine learning solutions across Canada. MVision AI’s specialists will be collaborating with Medron Medical System Inc.’s experts to undertake the distribution of the finest, most convenient, and consistent radiotherapy services.
“Innovation and the introduction of new modalities in radiation oncology have changed the landscape in how radiation therapy is delivered. The introduction of artificial intelligence (AI) in treatment planning is the beginning of a new era that will ultimately lead to greater accuracy in radiation dose delivery, leading to improved patient outcomes,” said Ronald Wallace, President of Medron Medical Systems Inc.
“Medron Medical Systems Inc. is proud to partner with MVision in developing the Canadian market of their Automatic Segmentation platform using their unique AI algorithms.”
As stated by MVision AI’s CEO and Co-Founder, Mahmudul Hasan, “MVision is continuing its rapid expansion. We are excited to start this partnership with Medron Medical Systems Inc. for Canadian hospitals. We are well ahead of our mission to serve radiotherapy patients with fast and high-quality treatment plans.”Back To Top
AI Segmentation Software for Radiation Therapy Planning Introduced in Canada. Appl Rad Oncol.